EAGAN, Minn.--(BUSINESS WIRE)--Biothera has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its cancer immunotherapy candidate Imprime PGG®.
Products selected as one of the Most Interesting Oncology Projects to Watch have met rigorous criteria, including unmet medical need, market potential, diversity of indications, strong science, partnering opportunities, and potential for new opportunities beyond initial indications.
Imprime PGG is a novel innate immune cell modulator that primes neutrophils, monocytes and macrophages through a complement receptor 3 (CR3)-dependent mechanism to exert anti-tumor activity against tumor cells that have been opsonized with complement following targeting with anti-tumor antibodies.
Help employers find you! Check out all the jobs and post your resume.
Products selected as one of the Most Interesting Oncology Projects to Watch have met rigorous criteria, including unmet medical need, market potential, diversity of indications, strong science, partnering opportunities, and potential for new opportunities beyond initial indications.
Imprime PGG is a novel innate immune cell modulator that primes neutrophils, monocytes and macrophages through a complement receptor 3 (CR3)-dependent mechanism to exert anti-tumor activity against tumor cells that have been opsonized with complement following targeting with anti-tumor antibodies.
Help employers find you! Check out all the jobs and post your resume.
